TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18387719
Drug: RTS,S/AS02 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS02 vaccine on a 0, 7, and 28 day schedule
Study: 12025912
Drug: Oxerutins (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxerutins (2 g/day for grade I CVI, 3 g/day for grade II CVI in the first 2 weeks; then 1 g/day for grade I CVI, 2 g/day for grade II CVI in the following 2 weeks)
Study: 10428191
Drug: Risperidone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (up to 2.0 mg/d) for 6 weeks
Study: 1974399
Drug: Loratadine 40
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine 40 mg
Study: 31325466
Drug: Silver diamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver diamine fluoride (SDF) solution
Study: 27593794
Drug: Fluoroscopy-guided caudal
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopy-guided caudal epidural steroid injection
Study: 24315625
Drug: Adjuvant anthracycline-based
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant anthracycline-based chemotherapy combined with taxanes
Study: 17545758
Drug: Chemotherapy (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Group 1)
Study: 17545758
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (Group 2)
Study: 9856712
Drug: Regularly administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regularly administered intramuscular injections of morphine
Study: 7832132
Drug: Intracoronary nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary nicorandil 1.5 mg in the left coronary artery
Study: 7832132
Drug: Intracoronary nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary nicorandil 1.0 mg in the right coronary artery
Study: 7832132
Drug: Intracoronary nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary nicorandil (various doses)
Study: 7192456
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 to 360 mg daily, mean 198 +/- 80 mg) for 3.5 weeks to 7 months (averaging 3 months)
Study: 30559343
Drug: Papacarie gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papacarie gel (caries removal with the chemical‐mechanical method)
Study: 26054549
Drug: Reimbursement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reimbursement of up to 50 US dollars for purchased vegetables (treatment group, n=69)
Study: 24365793
Drug: Oral NAC
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral NAC + i.v. saline
Study: 19762222
Drug: Budesonide/formoterol maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol maintenance and reliever therapy (160/4.5 microg bid and as needed)
Study: 19762222
Drug: Conventional best
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional best practice (CBP) (ICS or ICS/LABA+/−other agents at an approved dose plus as-needed SABA)
Study: 11401008
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg EMD
Study: 7989400
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methylprednisolone; short course; dosage not specified; duration not specified.
Study: 2658841
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day Tamoxifen
Study: 2658841
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day Tamoxifen
Study: 2658841
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation to 40 mg/day after 20 mg/day
Study: 4157346
Drug: One daily
Normalized name: One Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily intramuscular injection of 160 mg of gentamicin
Study: 4157346
Drug: Three injections
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections daily (60 or 80 mg every 8 h)
Study: 4157346
Drug: One daily
Normalized name: One Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily injection of gentamicin
Study: 4157346
Drug: Three injections
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections daily
Study: 29233097
Drug: DE-REACH intervention
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: DE-REACH intervention (12 individual two-weekly sessions, 9 at home, 3 via telephone)
Study: 23507477
Drug: HAM-RS2 (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAM-RS2 (48 g dietary fibre from high-amylose maize type 2 resistant starch)
Study: 19901711
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - Enoxaparin sodium 40mg/d
Study: 12498603
Drug: Infant orthopedics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant orthopedics (IO) treatment started within 2 weeks after birth until soft palate closure at 12 months of age.
Study: 12498603
Drug: Non-infant orthopedics
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-infant orthopedics (non-IO) treatment with extra check-ups at 6 weeks and before and after lip repair and soft palate closure.
Study: 17170610
Drug: Irbesartan/HCTZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ combination therapy (150 mg/12.5 mg, titrated to 300 mg/25 mg at week 1)
Study: 17170610
Drug: Irbesartan monotherapy
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan monotherapy (150 mg, titrated to 300 mg at week 1)
Study: 10516738
Drug: Irbesartan/HCTZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ combination therapy
Study: 17170610
Drug: Irbesartan monotherapy
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan monotherapy
Study: 10472868
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (10- or 20-mg patch)
Study: 10511361
Drug: Intravenous ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ritodrine
Study: 1902238
Drug: Erythromycin (333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (333 mg administered orally every 8 hr for 4 days)
Study: 1902238
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (glyburide 5 mg administered on day 4 of each study period)
Study: 28736381
Drug: Lisinopril treatment
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril treatment (experimental group)
Study: 28736381
Drug: Captopril treatment
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril treatment (control group)
Study: 24827134
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg once daily (after adjustment for baseline characteristics)
Study: 24827134
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg once daily (exploratory analysis)
Study: 19741011
Drug: MTX (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX (0.3 mg/kg/week, maximum of 20 mg/week, without escalating dose regimen)
Study: 19741011
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with MTX and ADA (40 mg eow)
Study: 19741011
Drug: MTX and
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX and ADA combination therapy
Study: 17971594
Drug: ATA +
Normalized name: Passiflora incarnata + valerian
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATA + TOR (Atamestane 500 mg + Toremifene 60 mg)
Study: 17971594
Drug: LET (Letrozole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LET (Letrozole 2.5 mg)
Study: 11790868
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg daily) for 3 weeks
Study: 11790868
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg daily) for 1 week
Study: 10147334
Drug: Multizone treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multizone treatments
Study: 10147334
Drug: Excimer laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excimer laser for compound myopic astigmatism
Study: 23475691
Drug: tofacitinib 2
Normalized name: tofacitinib 22 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 2 mg twice daily
Study: 22006202
Drug: tofacitinib 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 15 mg twice daily
Study: 21349585
Drug: Combined medical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined medical and psychological treatment (including antidepressants and health-visitor delivered non-directive counselling)
Study: 17063220
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of oral citalopram
Study: 12932601
Drug: Comparison group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison group (no atorvastatin)
Study: 16517515
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy (Control)
Study: 8403176
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg.kg‐1 i.v.
Study: 26845191
Drug: Axitinib (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (two 5‐mg tablets daily on days 2‐19)
Study: 26845191
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (pemetrexed 500 mg/m(2) every 3 weeks and cisplatin 75 mg/m(2) every 3 weeks)
Study: 20231678
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (paclitaxel 225 mg/m(2) and carboplatin AUC 6) followed by surgery
Study: 16438075
Drug: Subcutaneous closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous closure with 2/0 polyglactin sutures (Group-I)
Study: 16438075
Drug: No subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subcutaneous closure (Group-II)
Study: 6820918
Drug: TCUK and
Normalized name: TCUK
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCUK and UUK (combined with anti-cancer agents)
Study: 29909433
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray (100, 200, or 400 µg)
Study: 29909433
Drug: Fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl citrate IV 50 µg
Study: 27304975
Drug: Bethanechol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol 150 mg
Study: 27304975
Drug: Bethanechol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol (all doses)
Study: 12622859
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel (verum) used twice daily for 3 weeks
Study: 12622859
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel used twice daily for 3 weeks
Study: 10638906
Drug: SGB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGB with 7 ml of 1% lidocaine
Study: 8867248
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) at 3 g/kg and higher
Study: 8867248
Drug: Salicylic acid
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic acid (SA) at 15 g/kg
Study: 8867248
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) at 15 g/kg and salicylic acid (SA) at 15 g/kg
Study: 8867248
Drug: Commercial ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercial ibuprofen (50 g/kg)
Study: 8867248
Drug: Benzocain creams
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzocain creams (100 g/kg)
Study: 6125193
Drug: Pindolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (15 mg)
Study: 30998528
Drug: Coffee intake
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee intake (150 mL, 3 times per day until discharge)
Study: 30998528
Drug: Tea intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea intake (150 mL, 3 times per day until discharge)
Study: 26728501
Drug: modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified constraint-induced movement therapy (m-CIMT)
Study: 26728501
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group (conventional therapy)
Study: 19386949
Drug: Integrated Medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Medicines Management (IMM) program
Study: 10975216
Drug: ANP 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANP 0.025 mg x kg(‐1).min(‐1)
Study: 10975216
Drug: ANP 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANP 0.05 mg x kg(‐1) x min(‐1)
Study: 10975216
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ANP
Study: 1414321
Drug: SCMC-Lys (mucoregulatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCMC-Lys (mucoregulatory drug)
Study: 2865251
Drug: oral concentrate
Normalized name: pectoral concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral concentrate
Study: 2865251
Drug: intramuscular medication
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular medication
Study: 31660915
Drug: Integrated delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated delivery of mass drug administration (MDA) for soil-transmitted helminths (STH) and mass dog rabies vaccination (MDRV)
Study: 26815932
Drug: Oral systemic
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral systemic antibiotics
Study: 23257663
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab injection (IVRI) 0.5 mg/0.05 ml
Study: 16051446
Drug: Bromocriptine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (maximum dose 2.5mg po tid)
Study: 30911301
Drug: Autologous platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet released growth factor (APRGF) injection (1-2 cc)
Study: 30232851
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus fire-needle stimulation and cupping (Famciclovir 0.25 g three times a day, Mecobalamin 0.5 g three times a day, plus fire-needle stimulation and cupping once a day for 7 days)
Study: 30232851
Drug: Medication (Famciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Famciclovir 0.25 g three times a day, Mecobalamin 0.5 g three times a day)
Study: 27636931
Drug: Afobazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afobazole (30 mg/day)
Study: 27636931
Drug: Diazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (30 mg/day)
Study: 20064680
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of mixed nuts daily for 12 weeks
Study: 17938984
Drug: Raloxifene (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (after open-label treatment)
Study: 30467695
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after open-label treatment)
Study: 19425461
Drug: Manipulative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulative therapy plus physical therapy
Study: 15040936
Drug: Recombinant OprF-OprI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant OprF-OprI vaccine (intramuscular injection)
Study: 15040936
Drug: Recombinant OprF-OprI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant OprF-OprI vaccine (intranasal application)
Study: 8214656
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of bupivacaine (0.25%; 50 mg) intra‐articularly (IA) (Group 1)
Study: 8214656
Drug: Continuous three‐in‐one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous three‐in‐one lumbar plexus block using a catheter to administer 0.25 ml/kg of bupivacaine (0.25%; single‐shot) plus continuous pump infusion of the same drug (0.03 ml.kg‐1 x h‐1 of 0.25% bupivacaine for 24 h) (Group 2)
Study: 8214656
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of morphine with 20 ml of saline IA (Group 3)
Study: 3735103
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dothiepin hydrochloride
Study: 3735103
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dothiepin hydrochloride
Study: 3735103
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg dothiepin hydrochloride
Study: 22253054
Drug: DISE CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: DISE CPAP titration
Study: 19686304
Drug: School-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based intervention promoting sun protection and hat use; specific dosage and duration not applicable as this is baseline data before intervention.
Study: 12466733
Drug: Climodien (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climodien (2 mg estradiol and 2 mg dienogest)
Study: 12466733
Drug: Kliogest (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kliogest (2 mg estradiol and 1 mg norethisterone acetate)
Study: 2183633
Drug: Oral S-adenosylmethionine
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral S-adenosylmethionine
Study: 6445607
Drug: 40 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μg ipratropium bromide
Study: 6445607
Drug: 80 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 μg ipratropium bromide
Study: 6445607
Drug: 120 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 μg ipratropium bromide
Study: 25247950
Drug: Nonlinear blended
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonlinear blended images at a 25% reduced dose
Study: 25247950
Drug: Nonlinear blended
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonlinear blended images at a 50% reduced dose
Study: 25247950
Drug: Simulated 120-kVp
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated 120-kVp linear blended images at a full dose
Study: 10886086
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses (125, 250, 500 microg)
Study: 26950553
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg quetiapine IR
Study: 18608021
Drug: Anterior ultrasonography-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior ultrasonography-guided contrast injections
Study: 18608021
Drug: Posterior ultrasonography-guided
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior ultrasonography-guided contrast injections
Study: 16080637
Drug: Subcutaneous lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous lateral internal sphincterotomy using radiofrequency bistoury (Group A)
Study: 8026448
Drug: Caffeine 200
Normalized name: caffeine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 200 mg at 01:30 and 07:30
Study: 8026448
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prophylactic nap and caffeine
Study: 2685288
Drug: Mild analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild analgesics
Study: 2685288
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and ibuprofen
Study: 2685288
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or acetaminophen
Study: 24299975
Drug: Drotaverine hydrochloride
Normalized name: drotaverine hydrochloride
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotaverine hydrochloride (40mg) given at the start of the active phase of labor, repeated every 2 hours (maximum 3 doses)
Study: 18807576
Drug: Losartan-hydrochlorothiazide film-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan-hydrochlorothiazide film-coated tablet formulation
Study: 18807576
Drug: Hydrochlorothiazide film-coated
Normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide film-coated tablet formulation
Study: 16204712
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of (18)F‐FDG PET and APOE genotype
Study: 10207659
Drug: Citalopram (20‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20‐80 mg/day)
Study: 8597527
Drug: Flesinoxan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flesinoxan (1 mg, IV)
Study: 6123363
Drug: Beta-blockers (late
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (late intervention)